RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways https://www.biorxiv.org/content/10.1101/2023.06.09.544432v1?med=mas
RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways https://www.biorxiv.org/content/10.1101/2023.06.09.544432v1?med=mas